LETTER TO THE EDITOR
Carlos Wesley Lopes Brasil da Silva, DDSa, Beatriz Melare de Oliveira, DDSa, Jheinis Stefany Pascuineli Duarte, DDSa, Thalya Fernanda Hortsh Maltarollo, MSa, Henrico Badaoui Strazzi-Sahyon, PhDb,c and Gustavo Sivieri-Araujo, PhDa
aDepartment of Preventive and Restorative Dentistry, Discipline of Endodontics, Araçatuba School of Dentistry, São Paulo State University – UNESP, Araçatuba, Brazil; bDepartment of Prosthodontics and Periodontology, Bauru School of Dentistry, University of São Paulo – USP, Bauru, Brazil; cDivision of Biomaterial and Biomedical Sciences, Department of Oral Rehabilitation and Biosciences, Oregon Health & Science University, OHSU, Portland, OR, USA
KEYWORDS: Tumor necrosis factor-alpha; biomarkers; dental pulp necrosis
Citation: ACTA ODONTOLOGICA SCANDINAVICA 2025; VOL. 84: 93–94. DOI: https://doi.org/10.2340/aos.v84.43034.
Copyright: © 2025 The Author(s). Published by MJS Publishing on behalf of Acta Odontologica Scandinavica Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
Received: 9 December 2024; Accepted: 23 January 2025; Published: 27 February 2025.
CONTACT Professor Gustavo Sivieri-Araujo gustavo.sivieri@unesp.br / gustavosivieri@uol.com.br Department of Preventive and Restorative Dentistry, Discipline of Endodontics, São Paulo State University (UNESP) School of Dentistry, Araçatuba, Rua José Bonifácio, 1193, 16015-050 Araçatuba, SP-BRAZIL
Competing interests and funding: The authors all equally contributed to the work in this manuscript.
There is no funding source to report for this letter/commentary.
The authors declare no conflicts of interest.
Dear Editor,
Apical periodontitis and pulp necrosis are conditions that arise from the host’s immune response to microbial invasion within the dental pulp. This inflammatory process progressively degrades pulp tissue and, in advanced stages, may lead to necrosis. These diseases are clinically significant and highly prevalent worldwide, with recent studies showing that apical periodontitis affects roughly 50% of the global adult population. The prevalence is even higher in dental clinic populations and hospital settings [1].
A crucial component of the inflammatory response is the release of cytokines and interleukins, particularly interleukin-1β and tumor necrosis factor-α (TNF-α), both of which play significant roles in tissue breakdown during pulpitis [2]. Notably, TNF-α has been observed to increase protein levels during pulp inflammation, potentially correlating with the progression of inflammatory damage [2].
Patients with comorbidities such as type 2 diabetes face unique challenges due to the interplay between systemic conditions and local inflammatory responses, which can complicate diagnosis and idealize treatment strategies. Consequently, the application of biomarkers holds significant potential for facilitating earlier diagnoses and guiding optimal therapeutic approaches in such cases. Biomarkers, defined as measurable indicators of a biological state or condition, can provide valuable insights into the degree of tissue inflammation, thereby enhancing diagnostic precision and informing targeted therapeutic interventions [3].
Accordingly, biomarkers capable of indicating the degree of pulp inflammation and the onset of necrosis hold significant clinical value by enabling more conservative treatment approaches and improving the strategic planning of clinical interventions.
A biomarker is a biological observation that predicts a clinically relevant outcome, as defined by the NIH Definitions Working Group (2000) and the Biomarkers Definitions Working Group (2001) [3]. Biomarkers are widely utilized and serve as essential tools in various diagnostic contexts.
In a more recent definition, a biomarker can be described as ‘a functional variant or quantitative index of a biological process that predicts or reflects the evolution or predisposition to a disease or a response to therapy’ [3]. This definition highlights the critical role of biomarkers not only in diagnosing conditions but also in monitoring disease progression and therapeutic responses.
Thus, the primary objective of a biomarker is to facilitate precise clinical diagnoses of patient conditions, ensuring replicability and accuracy. These characteristics are essential for a biomarker to be considered effective and reliable in clinical practice.
Interleukins are closely linked to inflammatory processes, and in the context of pulp necrosis and the underlying mechanisms of this pathological condition, TNF-α plays a pivotal role in bone resorption within periapical lesions [4, 5]. TNF-α is critical in modulating the inflammatory response in pulp tissues, being integral to pathological processes such as pulp necrosis, as detailed by Taira et al. [4]. Upon activation by inflammatory stimuli, TNF-α binds to specific receptors on target cells, initiating a signaling cascade that results in the expression of pro-inflammatory cytokines and the activation of osteoclasts, which are responsible for bone resorption [6]. Additionally, TNF-α activation, via the ERK (extracellular signal-regulated kinase) pathway, not only promotes the differentiation of odontogenic cells but also enhances osteoclastic activity [4, 6].
The presence of comorbidities such as type 2 diabetes can complicate the inflammatory response in the dental pulp and influence the progression of pulp necrosis. Recent studies, such as that by Agrawal et al. [5], support the hypothesis that TNF-α concentration in diabetic patients with pulpal inflammation is significantly altered, reflecting the interaction between systemic conditions and local inflammatory processes. However, Alsamahi et al. [7] emphasize that the expression of inflammatory cells in diabetic patients is associated with macrophage markers, indicating an exacerbated immune response. This supports the use of biomarkers to develop more effective therapeutic strategies.
Furthermore, TNF-α exhibits a synergistic response in the context of an induced inflammatory environment, with an increase in osteoclasts corresponding to elevated interleukin concentrations, as demonstrated by Taira et al. [4]. Additionally, in the context of type 2 diabetes and pulp necrosis, the expression of inflammatory cells has been linked to the upregulation of genes associated with macrophage synthesis and dendritic cell markers, particularly when related to interleukin levels [7].
The significant correlation between interleukin concentration and macrophage synthesis suggests a potential link to bone resorption observed in pulp necrosis. This relationship could provide valuable insights for early diagnosis and the development of targeted treatment strategies for this condition.
Given the current research on the subject, the pursuit of biomarkers appears to be a promising trend. In this context, the application of TNF-α as a potential biomarker for pulp necrosis shows promise. However, it is essential to further investigate whether a reliable correlation exists between interleukin concentration and the pathology to establish its clinical reliability. The interaction between systemic conditions, such as type 2 diabetes, and localized inflammatory responses significantly contributes to the complexity of pulp necrosis progression and diagnosis. Exploring the potential of TNF-α as a biomarker in these scenarios may facilitate early detection and optimize therapeutic strategies, particularly for individuals with comorbidities. Ultimately, studies focused on exploring TNF-α as a biomarker for pulp necrosis are crucial to clarify these points and validate its potential in clinical practice.
[1] Tibúrcio-Machado CS, Michelon C, Zanatta FB, Gomes MS, Marin JA, Bier CA. The global prevalence of apical periodontitis: a systematic review and meta-analysis. Int Endod J. 2021;54(5):712–35. https://doi.org/10.1111/iej.13467
[2] Zanini M, Meyer E, Simon S. Pulp inflammation diagnosis from clinical to inflammatory mediators: a systematic review. J Endod. 2017;43(7):1033–51. https://doi.org/10.1016/j.joen.2017.02.009
[3] Aronson JK, Ferner RE. Biomarkers – a general review. Curr Protoc Pharmacol. 2017;76:9.23.1–17. https://doi.org/10.1002/cpph.19
[4] Taira TM, Lima V, Prado DS, Silva TA, Issa JPM, da Silva LAB, et al. NLRP12 attenuates inflammatory bone loss in experimental apical periodontitis. J Dent Res. 2019;98(4):476–84. https://doi.org/10.1177/0022034518820289
[5] Agrawal S, Taneja S, Shetty D, Gopikrishna V, Bhalla VK. Evaluating the concentration of MMP-9 and TNF- α in pulpal blood at various stages of pulpal inflammation in diabetics: a cross sectional study. Eur Endod J. 2023;8(4):286–92. https://doi.org/10.14744/eej.2023.41736
[6] Zhang Y, Lian M, Zhao X, Cao P, Xiao J, Shen S, et al. RICK regulates the odontogenic differentiation of dental pulp stem cells through activation of TNF-α via the ERK and not through NF-κB signaling pathway. Cell Biol Int. 2021;45(3):569–79. https://doi.org/10.1002/cbin.11498
[7] Alsamahi S, Milne TM, Hussaini H, Rich AM, Friedlander LT. Type 2 diabetes and the clinically normal pulp: an in vitro study. Int Endod J. 2022;55(6):660–671. https://doi.org/10.1111/iej.13732